US equities |
SPCX $167.45 ▲+5.34% NVDA $236.34 ▲+1.02% MU $1,064.92 ▼-0.93% TSLA $378.33 ▲+2.09% MSFT $525.78 ▲+1.60% SNDK $1,708.61 ▼-0.66% INTC $117.43 ▼-1.59% META $744.38 ▲+2.24%
FinancialContent

Hikma Pharmaceuticals Plc. (OP:HKMPY)

43.00 UNCHANGED
Last Price Updated: 9:30 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hikma Pharmaceuticals Plc.

News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
News headline image
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices ↗
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... 
Via Benzinga
News headline image
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
News headline image
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape ↗
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March.  Methotrexate is an injected medication utilized to treat... 
Via Benzinga
News headline image
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
From Junshi Biosciences
Via GlobeNewswire
News headline image
Friday Markets News ↗
Methane leaks in the Permian Basin are 6 times higher than estimates. 
Via Talk Markets
News headline image
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
From Bio-Thera Solutions, Ltd.
Via Business Wire
News headline image
Summer Friday ↗
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets